GPhA: AbbVie's Petition A Ploy To Delay Interchangeables
This article was originally published in Scrip
Executive Summary
AbbVie Inc.'s citizen petition calling for a public hearing before the FDA issues its long-awaited biosimilars guidance on interchangebility is nothing more than a "thinly disguised" ploy to block cheaper biologics that may be substituted for the brand-name products, the Generic Pharmaceutical Association (GPhA) and its affiliated Biosimilars Council argued in public comments submitted to the US regulatory agency.